Global Drug of Abuse (DOA) Testing Market – Analysis and Forecast (2018-2024)
Drug of Abuse (DOA) testing is the clinical detection of one or more drugs within the human system, by sample testing. This is done to provide clinical intervention or for monitoring of illegal drug intake. Global DOA testing market was poised at USD 4,938.6 million in 2017. The testing for DOA requires products such as immunoassay analyzers, chromatography instruments, breath analyzers, rapid test kits, and assay kits & reagents. The rapid test kits are driving the growth of the DOA testing market and are estimated to hold the largest share in 2017. Download Free Report Sample At: https://www.vynzresearch.com/healthcare/drug-of-abuse-doa-testing-market/request-sample The increase in production, consumption and trade for new and illicit drugs will lead to high demand of DOA testing that will drive the growth of industry. According to the World Drug Report 2017 by UNODC, the annual prevalence of all illicit drug use is 5.3% with 255 million numbers of users in 2015. This will necessitate the need for DOA testing and will thereby drive the growth of the market. The government initiatives to raise awareness against DOA and rise in organizational compliance for DOA testing will render to the growth of the overall market. The high demand of products with increased specificity and sensitivity towards designer drugs will also add to the growth of the industry. Geographically, North America accounts for the largest share in the DOA testing market, globally. This contribution is due to the adaptation of technologically advanced products for DOA testing, increased demand for illicit drugs in the region, large scale drug trafficking, and the increasing government initiative to spread awareness against DOA. Moreover, the DOA testing industry is expected to be witness the fastest growth in Asia-Pacific. Read More: https://www.vynzresearch.com/healthcare/drug-of-abuse-doa-testing-market The major player in the global DOA testing market includes Danaher Corporation, Siemens AG, Merck KGaA, Dru00e4gerwerk AG & Co. KGaA, bioMu00e9rieux S.A., Waters Corporation, F. Hoffmann-La Roche AG, Quest Diagnostics Inc., Laboratory Corporation of America Holdings, Abbott Laboratories, ThermoFisher Scientific Inc., Express Diagnostics Int'l, Inc., Randox Laboratories Ltd., Psychemedics Corporation, and Bio-Rad Laboratories, Inc. The leading players through acquisitions are attaining competency and larger market share in the global DOA testing industry. For example, in January 2018, ACM Global Laboratories, an affiliate of Rochester Regional Health announced the strategic acquisition of DrugScan, Inc. and DSI Medical Services, Inc. The acquisition was made to establish a laboratory service portfolio and drug testing capabilities.
74 views • 6 slides